Cognitive and structural brain changes in ofatumumab-treated multiple sclerosis: A longitudinal study
{{output}}
Anti-CD20 therapies control inflammatory activity in multiple sclerosis (MS), but their effects on neurodegeneration and cognition in real-world settings remain uncertain. We conducted a longitudinal observational study of relapsing MS (RMS) patients treated w... ...
